Dublin, Ireland – Shire, a specialty biopharmaceutical company, announces the retirement of chief executive Angus Russell in 2013 after 13 years with the company and 32 years in the pharmaceutical industry.[break]
Mr. Russell was appointed Chief Executive Officer on June 18, 2008 and has been a member of the Board since December 13, 1999. He is also Chairman of the Company’s Leadership Team. Mr. Russell was the Company’s Chief Financial Officer from December 1999 to June 2008.
Mr. Russell is a Non - October 25, 2012, Dublin, Ireland – Shire, a specialty biopharmaceutical company, announces the retirement of chief executive Angus Russell in 2013 after 13 years with the company and 32 years in the pharmaceutical industry.
Article continues below
]
Mr. Russell was appointed Chief Executive Officer on June 18, 2008 and has been a member of the Board since December 13, 1999. He is also Chairman of the Company’s Leadership Team. Mr. Russell was the Company’s Chief Financial Officer from December 1999 to June 2008.
Mr. Russell is a Non-Executive Director of InterMune, Inc. and is a former Non-Executive Director of the City of London Investment Trust plc. Between 1980 and 1999, he held a number of positions of increasing responsibility at ICI, Zeneca and AstraZeneca PLC, including Vice President, Corporate Finance at AstraZeneca and Group Treasurer at Zeneca. Mr. Russell is a Chartered Accountant and is a Fellow of the Association of Corporate Treasurers.
Flemming Ornskov MD, MBA, MPH will join the Shire Board as Chief Executive Designate on January 2, 2013 following completion of his notice period with his current employer.
Dr. Ornskov joins from Bayer where, as Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine he oversees the full pharmaceutical product portfolio in Europe, China and the US.
Dr. Ornskov currently manages the global business unit, Women´s Health and General Medicine, at Bayer Schering Pharma AG. Prior to that, he held a variety of executive positions in the healthcare, pharmaceutical industries, notably within Merck & Co as Senior Marketing Director – Osteoporosis and Franchise Business Group Leader – Urology and with Novartis where he headed the US Cardiovascular Therapeutic Franchise and subsequently the Ophthalmics Business Unit as well as Bausch & Lomb, INc where he was President of Pharmaceuticals and OTC. ■
LATEST MOVES FROM Dublin, Ireland – Shire, a specialty biopharmaceutical company, announces the retirement of chief executive Angus Russell in 2013 after 13 years with the company and 32 years in the pharmaceutical industry.[break]
Mr. Russell was appointed Chief Executive Officer on June 18, 2008 and has been a member of the Board sinc